Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aligos Therapeutics Inc ALGS

Healthcare Biotechnology
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug... see more

Recent & Breaking News (NDAQ:ALGS)

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

GlobeNewswire September 21, 2023

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023

GlobeNewswire July 27, 2023

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

GlobeNewswire July 19, 2023

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

GlobeNewswire June 21, 2023

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

GlobeNewswire June 7, 2023

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

GlobeNewswire May 24, 2023

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

GlobeNewswire May 12, 2023

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

GlobeNewswire April 27, 2023

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

GlobeNewswire April 11, 2023

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

GlobeNewswire March 29, 2023

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 9, 2023

Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

GlobeNewswire February 28, 2023

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

GlobeNewswire February 16, 2023

Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

GlobeNewswire February 14, 2023

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 10, 2023

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

GlobeNewswire February 8, 2023

Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

GlobeNewswire January 5, 2023

Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

GlobeNewswire December 14, 2022